DexCom, Inc. (NASDAQ:DXCM) Short Interest Up 11.7% in September

DexCom, Inc. (NASDAQ:DXCM) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 9,550,000 shares, an increase of 11.7% from the September 15th total of 8,550,000 shares. Based on an average daily volume of 5,640,000 shares, the days-to-cover ratio is presently 1.7 days.

DexCom Price Performance

DexCom stock traded down $0.19 during mid-day trading on Thursday, hitting $69.71. 248,036 shares of the company were exchanged, compared to its average volume of 3,812,003. The business has a fifty day moving average of $69.95 and a 200 day moving average of $101.15. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market capitalization of $27.72 billion, a PE ratio of 45.10, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the company posted $0.34 earnings per share. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. As a group, sell-side analysts expect that DexCom will post 1.69 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

Several large investors have recently bought and sold shares of DXCM. Team Hewins LLC grew its holdings in DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after purchasing an additional 83 shares during the period. Bleakley Financial Group LLC raised its holdings in shares of DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares during the period. Capital Insight Partners LLC grew its holdings in DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares during the period. Gulf International Bank UK Ltd boosted its holdings in shares of DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after buying an additional 93 shares during the period. Finally, Harbor Investment Advisory LLC grew its position in shares of DexCom by 13.1% during the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after purchasing an additional 100 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research reports. Morgan Stanley dropped their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. BTIG Research lowered their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Wells Fargo & Company reduced their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, October 12th. Finally, Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $110.73.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.